No black box warning on record for Yargesa

As of the latest FDA labeling reviewed, Yargesa (MIGLUSTAT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Yargesa medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Peripheral neuropathy: Perform baseline and follow-up neurological evaluations at 6-month intervals in all patients ( 5.1 ). • Tremor: Reduce dose to ameliorate tremor or discontinue treatment if tremor does not resolve within days of dose reduction ( 5.2 ). • Diarrhea and weight loss: Evaluate for underlying gastrointestinal disease in patients who do not respond to u

No black box warning on record for Yargesa

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Peripheral neuropathy: Perform baseline and follow-up neurological evaluations at 6-month intervals in all patients ( 5.1 ). • Tremor: Reduce dose to ameliorate tremor or discontinue treatment if tremor does not resolve within days of dose reduction ( 5.2 ). • Diarrhea and weight loss: Evaluate for underlying gastrointestinal disease in patients who do not respond to u

Yargesa Black Box Warning

No black box warning on record for Yargesa

Other warnings & precautions

Yargesa Black Box Warning

No black box warning on record for Yargesa

Other warnings & precautions